Avigen, Inc. is a biopharmaceutical company that has focused on identifying and developing differentiated products to treat patients with serious disorders. The Company’s potential product is AV411, a glial attenuator, for neuropathic pain and opioid withdrawal and methamphetamine addiction. The Company is a development-stage company. Prior to October 2008, it had been developing a product candidate, AV650, for the treatment of spasticity associated with multiple sclerosis. In December 2008, it completed a sale of its early-stage AV513 program to Baxter Healthcare Corporation.